2019/20 Condensed Annual Report Your Specialist for Hazardous Reactions.
3 DOTTIKON ES
Condensed Annual Report 2019/20
Content
Summary/Outlook
5
Group Financial Statements DOTTIKON ES Group
15
Consolidated Income Statements
16
Consolidated Balance Sheets
17
Consolidated Cash Flow Statements
18
Consolidated Statements of Changes in Equity
19
Notes
20
Corporate Governance
27
Investor Relations
37
The Annual Report 2019/20 in English includes only condensed financial information.
The comprehensive Annual Report 2019/20 is available in German.
5 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
Dear Shareholder,
Herewith we present to you DOTTIKON ES Group's Condensed Annual Report 2019/20 for the period from April 1, 2019, to March 31, 2020. The fourth quarter of the business year fell into the period of the COVID-19 pandemic, which was initially limited to China but soon spread around the globe. The conscientious commitment of our employees and the employees of our suppliers on site, in compliance with the applicable hygiene and behavior rules, secured the production and timely delivery of vital APIs for life-saving medication even during the pan demic. This year's Annual Report is therefore dedicated to all these employees and shows perspectives from various vantage points taken on our site in Dottikon (Aargau, Switzerland).
Review
At CHF 174.8 million, net sales in the business year 2019/20 were 18.3 percent higher than in the previous year and were broad-based in terms of products and customers. The production output for the full business year - net sales plus inventory changes in semi-finished and finished goods - increased by 15.7 percent compared to the previous year. The CHF 10.2 million increase in semi-finished and finished goods reflects the high order volume for the ongoing business year 2020/21. Capitalized own production and hence other operating income increased due to significant investments in new production capacities. Material expenses stood at CHF 44.8 mil- lion, representing 24.2 percent of the production output, and were slightly below the previous- year figure in relative terms. Personnel expenses rose by CHF 3.6 million or 5.4 percent to CHF 69.9 million. The increase was in equal proportion due to the 2.4 percent staff buildup and to
6 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
7 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
higher wages. In combination with higher other operating expenses, earnings before interest, taxes, depreciation, and amortization (EBITDA) were CHF 55.4 million, up 39.0 percent compared to the previous year, while the EBITDA margin was 31.7 percent (previous year: 27.0 per- cent). Due to an impairment charge in the previous year, depreciation and amortization at CHF
18.9 million was CHF 0.8 million lower compared to the previous year despite commissioning the new lab building for research and development as well as quality management and additional chemical production capacities. Earnings before interest and taxes (EBIT) stood at CHF 36.5 million, 80.9 percent higher than in the previous year, and the EBIT margin was 20.9 percent (previous year: 13.6 percent). The financial result was CHF 2.1 million higher than in the previ- ous year, mainly due to the valuation of the employer contribution reserve related to higher pen- sion fund investment returns. With the Federal Act on Tax Reform and AHV Financing coming into effect, and due to the application of the additional tax deduction for research and develop- ment expenses contained therein, income taxes were CHF 4.8 million owing to the high share
KEY FIGURES, APRIL-MARCH
CHF million
2018/19
2019/20
Changes
Net sales
147.7
174.8
18.3%
EBITDA
39.9
55.4
39.0%
EBITDA margin (in % of net sales)
27.0%
31.7%
EBIT
20.2
36.5
80.9%
EBIT margin (in % of net sales)
13.6%
20.9%
Net income
16.3
33.2
104.0%
Net income margin (in % of net sales)
11.0%
19.0%
Cash flow from operating activities
38.2
43.7
14.5%
of research and development activities. This translates into a tax rate of around 13 percent (pre- vious year: around 17 percent). Net income stood at CHF 33.2 million (previous year: CHF 16.3 million), and the net income margin was 19.0 percent (previous year: 11.0 percent).
The cash flow from operating activities stood at CHF 43.7 million, up 14.5 percent compared to the previous year. Cash outflows from investments were CHF 44.4 million, 9.1 percent lower than in the previous year. Cash and cash equivalents decreased slightly to CHF 42.8 million (pre- vious year: CHF 43.8 million). The equity ratio is a strong 82.1 percent.
Assessment of situation
The United States, China, and Russia continue to establish and lead a tripolar world order. The COVID-19 pandemic has unmasked the vulnerability and interdependence of these opponents. Europe is crumbling, which will spark nationalism and secession efforts after the pandemic. This fuels the potential for economic, fiscal, as well as military conflicts.
The major strategies to combat SARS-CoV-2 have created a generational conflict paradox: The older generation is protected at the expense of the younger generation's future, who in turn today live off the wealth created by the older generation. The desperate attempt to return from the mitigation to the containment phase with lockdown measures will result in a major delay in establishing herd immunity and generate considerable economic damage. With this strategy, global economic mobility can only be regained with the wide availability of a vaccine, provided that the protective measures implemented by the individual nations are lifted by then.
Because of the lockdown measures in response to the pandemic, the global economy has experienced an abrupt collapse and has been in steep decline since February 2020. For the first time
Employees (FTE, annual average)
592
606
2.4%
8 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
9 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
since the Great Depression of the 1930s, industrialized, emerging, and developing economies will simultaneously slide into recession. Existing global debt has risen further from its previous record high, and the increasingly expansive monetary policies implemented to soften the blow from the adverse impact of the lockdown measures further aggravate this situation and are set to burden the global economic development in the long term. The COVID-19 crisis has bluntly revealed the risks and interdependencies within the global value chains created by a long phase characterized by global economies of scale and the outsourcing of key value chain segments. Values such as consistency, reliability, and trust, as well as cultural and regional proximity become increasingly important amid the crisis and establish the foundation of trust for future economic as well as political relations. If this development results in more broadly based regional supply chains, the costs for goods will inevitably rise. In combination with the decisively expansive monetary policies, this could result in inflation. Such a scenario would force central banks to deviate from their low interest rate policies, which would bring about potentially disastrous increases in interest rates for heavily indebted countries, companies, and individuals.
Demographic developments, accelerated market approvals for generics, biosimilars, and novel drugs, government attempts to reduce drug prices, as well as a steep rise in drug demand in China remain key medium- and long-term volume growth and innovation drivers in the pharmaceutical market. The demographic trends ensure further long-term volume growth. Global life expectancy continues to rise, even if it is at lower rates than in the previous years in industrialized countries. In the short term, there will be a COVID-19 effect related to the clearly higher mortality rate among over-65-year-olds. In the most important drug sales nations, the 65+ age group represents between 11 (China) and 28 percent (Japan) of the population. If over a
long period, neither a vaccine nor new drug treatments to drastically reduce the SARS-CoV-2 infection or COVID-19 mortality rates are available, global annual drug sales could plummet by around CHF 50 billion. In addition, the development of drug candidates unrelated to COVID-19 will be adversely affected when hospitals are overwhelmed. Once the crisis is over, cost pressure in the health care system is likely to diminish given an increase in health awareness, despite the fact that governments will need to cut their budgets in light of higher government debt.
Despite this development, global drug spending will surpass the CHF 1'000 billion mark in the years ahead. In developed markets, the strong increase in spending on novel specialty drugs is offset by lower prices for the most important drugs on the back of a loss of exclusivity. In con- trast, in pharmerging markets, the increase in access to the health care system seen over the last decade and the respective volume and spending growth are slowing down. On the one hand, the increase in global drug spending is due to a wider use of primarily generic diabetes, respiratory tract, cardiovascular, and oncology drugs. On the other hand, it is attributable to new specialty drugs and innovative products, which currently make up 36 percent of global drug spending and, with annual growth rates of 5 to 8 percent, continue to inch closer to a sales share of 40 percent. The respective sales growth is most significant in developed pharma markets, which represent over 60 percent of global drug sales. In these markets, their share is already 44 percent, with an expected increase to 52 percent over the coming five years. Just as before, strong profitable growth over the coming five years will therefore be fueled by specialty drug sales in developed markets. In 2019, the FDA approved 48 new drugs, 38 of which were small molecules and a further 10 were biologics. The share of biologics among drug candidates that await their approval has increased further in 2019, reaching 40 percent despite higher develop-
10 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
11 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
ment costs as well as far more demanding requirements in terms of quality and supply chain management. Even so, small molecules are set to defend their global drug sales market share of a little over two thirds over the next five years, with half of this share attributable to patent- protected or branded generic small molecule drugs, while biologics only account for 20 percent. The market for so-called Custom Development and Manufacturing Organizations (CDMOs) is set to grow by 7 percent over the coming five years on the back of the underlying pharma volume market growth and the growing outsourcing trend. The main drivers are, on the one hand, large pharmaceutical companies which have previously only outsourced 20 percent of newly approved drugs and now increasingly opt for in-house manufacturing of biologics while instead outsourcing small molecule manufacturing; and on the other hand, small and medium-sized biotechs which outsource roughly 80 percent and now increasingly gain market shares among newly approved drugs.
Given that biologics, biosimilars, cell and genetic therapy, as well as drug product manufacturing and sterile filling promised higher relative growth and margins compared to small molecule API manufacturing, CDMOs have invested heavily in these areas by means of acquisitions as well as buildup and expansion efforts. In addition to debottlenecking and expansion investments in existing production plants, however, there was hardly any buildup of new small molecule API production capacity. The trend to repatriate drug substance and drug product manufacturing to the West, driven by concerns regarding quality and reliability, is still ongoing and gains further traction on the back of China's strict enforcement of environmental requirements, its reduction in the number of chemical parks and a further intensification of the trade dispute between the United States and China. It is safe to assume that the COVID-19 crisis will have a
similar effect. As a result, shortages in high-quality and technologically versatile process development and API manufacturing capacities are inevitable.
Outlook
In the current market and pharmaceutical environment and with the continuously expanded chemical process development as well as the analytical and API manufacturing capacities at its Dottikon site in Switzerland, DOTTIKON ES is well positioned to capture the imminent small molecule growth potential in the short term, and secure it with ongoing expansion investments in the medium term, as well as with the construction of new production plants in the long term. The corporate strategy - strategic partner and specialist for hazardous reactions - is reaffirmed: By using enabling technology, we develop and manufacture high-quality, demanding chemical products safely and efficiently. We cultivate an integrated partnership with our customers. By applying our full development and manufacturing capabilities, we support our customers in the successful execution of their strategy. In doing so, we create more value for our customers than our competitors. We continue to focus on safety, reliability, high flexibility, and speed, and are thus strengthening our position as strategic development and manufacturing partner and performance leader.
The small molecules pharmaceutical market is and remains our main market with ongoing growth potential. The utilization of existing plants is increased with targeted debottlenecking investments to facilitate the capturing of the expected medium-term sales growth. The planning of a new multipurpose API production plant to secure long-term growth has reached a stage that allows for the beginning of construction during the ongoing business year 2020/21. At the same
12 Summary/Outlook DOTTIKON ES Group
Condensed Annual Report 2019/20
time, we have initiated the planning for additional pilot plant and API drying capacities. Against this background, investments will remain high also for the ongoing business year 2020/21. From today's point of view, initial external financing options for 2020 to finance the capacity expansion plans are in preparation. In order to ensure long-term growth, our independent Performance Chemicals project team continues to develop new, innovative proprietary products to satisfy currently unmet market needs outside the pharmaceutical market and brings these products closer to market readiness.
For the ongoing full business year 2020/21, we expect net sales above the previous year's figure.
Dottikon, May 14, 2020
Dr. Markus Blocher
Chairman of the Board of Directors
15
Condensed Annual Report 2019/20
Group Financial
Statements
DOTTIKON ES Group
16 Group Financial Statements DOTTIKON ES Group
Condensed Annual Report 2019/20
Consolidated Income Statements
April-March
CHF thousand and % (condensed)
Notes
2018/19
%
2019/20
%
Net sales
147'710
100.0
174'770
100.0
Changes in semi-finished and finished goods
12'153
10'189
Other operating income
5'421
6'385
Material expenses
-39'493
-44'846
Personnel expenses
(2)
-66'267
-69'852
Other operating expenses
(3)
-19'659
-21'238
Operating result before depreciation
and amortization (EBITDA)
39'865
27.0
55'408
31.7
Depreciation and amortization
(8, 9)
-19'706
-18'940
Operating result (EBIT)
20'159
13.6
36'468
20.9
Financial income
800
1'929
Financial expenses
-1'376
-420
Financial result
(4)
-576
1'509
Result from associated companies
21
19
Net income before taxes
19'604
13.3
37'996
21.7
Income taxes
(5)
-3'347
-4'837
Net income
16'257
11.0
33'159
19.0
Basic/diluted earnings per share in CHF
13.00
26.48
Weighted average number of shares
1'250'948
1'252'264
17 Group Financial Statements DOTTIKON ES Group
Condensed Annual Report 2019/20
Consolidated Balance Sheets
CHF thousand and % (condensed)
Notes
31.03.2019
%
31.03.2020
%
Cash and cash equivalents
43'833
42'843
Current financial assets
0
0
Trade receivables
(6)
41'202
35'144
Other receivables
1'541
2'373
Inventories
(7)
67'088
78'656
Prepaid expenses and accrued income
1'198
1'440
Current assets
154'862
33.4
160'456
32.8
Property, plant and equipment
(8)
263'963
283'679
Intangible assets
(9)
729
592
Investments in associated companies
1'253
1'272
Assets from employer contribution reserve
42'284
43'843
Non-current assets
308'229
66.6
329'386
67.2
Assets
463'091
100.0
489'842 100.0
Trade payables
12'751
10'397
Income tax liabilities
1'276
2'622
Other current liabilities
17'588
15'374
Current provisions
(10)
50
48
Accrued expenses and deferred income
26'545
23'226
Current liabilities
58'210
12.6
51'667
10.5
Non-current provisions
(10)
5'420
5'420
Deferred tax liabilities
(5)
31'121
30'805
Non-current liabilities
36'541
7.9
36'225
7.4
Liabilities
94'751
20.5
87'892
17.9
Share capital
127
127
Share premium
61'826
62'158
Retained earnings
310'744
343'746
Own shares
-4'357
-4'081
Shareholders' equity
368'340
79.5
401'950
82.1
Shareholders' equity and liabilities
463'091
100.0
489'842
100.0
18 Group Financial Statements DOTTIKON ES Group
Condensed Annual Report 2019/20
Consolidated Cash Flow Statements
April-March CHF thousand (condensed)
Notes
2018/19
2019/20
Net income
16'257
33'159
Income taxes
(5)
3'347
4'837
Financial result
(4)
576
-1'509
Depreciation of property, plant and equipment
(8)
19'509
18'708
Amortization of intangible assets
(9)
197
232
Result from associated companies
-21
-19
Other non-cash income and expenses
316
1'091
Interest received
(4)
35
5
Interest paid
(4)
-15
-13
Income taxes paid
(5)
-4'569
-3'771
Changes in
Trade receivables
12'727
6'068
Other receivables as well as prepaid expenses and accrued income
-1'066
-1'122
Inventories
(7)
-14'945
-11'568
Trade payables
2'599
-1'560
Other current liabilities as well as accrued expenses
and deferred income
3'244
-834
Provisions
(10)
-15
-2
Cash flow from operating activities
38'176
43'702
Outflows of
Current financial assets
0
0
Property, plant and equipment
(8)
-48'347
-44'245
19 Group Financial Statements DOTTIKON ES Group
Consolidated Statements of Changes in Equity
CHF thousand
AChanges in own shares in the reporting year 2019/20:
(condensed)
disposal of 1'367 shares within the shareholding program for employees
(previous year: disposal of 857 shares within the shareholding program
for employees)
Share capital
Share premium
Changes in fair value of foreign exchange forwards
Condensed Annual Report 2019/20
Other retained earnings
Own sharesA
Shareholders' equity
Intangible assets
(9)
-463
-159
Inflows of
Current financial assets
0
0
Property, plant and equipment
(8)
0
20
Intangible assets
(9)
0
0
Cash flow from investing activities
-48'810
-44'384
Dividends paid
0
0
Purchase of own shares
0
0
Disposal of own shares
0
0
Cash flow from financing activities
0
0
Currency translation effect on cash and cash equivalents
-114
-308
Net change in cash and cash equivalents
-10'748
-990
Cash and cash equivalents at the beginning of the reporting period
54'581
43'833
Balance 01.04.2018
127
61'358
37
294'470
-4'517
351'475
Net income
16'257
16'257
Changes of foreign exchange forwards
-25
-25
Income taxes on items recognized directly in equity
5
5
Dividends paid
0
Changes in own shares
468
160
628
Balance 31.03.2019
127
61'826
17
310'727
-4'357
368'340
Balance 01.04.2019
127
61'826
17
310'727
-4'357
368'340
Net income
33'159
33'159
Changes of foreign exchange forwards
-193
-193
Income taxes on items recognized directly in equity
36
36
Dividends paid
0
Changes in own shares
332
276
608
Cash and cash equivalents at the end of the reporting period
43'833
42'843
Balance 31.03.2020
127
62'158
-140
343'886
-4'081
401'950
20 Notes DOTTIKON ES Group
Condensed Annual Report 2019/20
Notes to the Group Financial Statements of DOTTIKON ES Group (condensed)
21 Notes DOTTIKON ES Group
Condensed Annual Report 2019/20
1 SEGMENT REPORTING
DOTTIKON ES Group manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. DOTTIKON ES Group is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. DOTTIKON ES Group uses, maintains, and continuously expands its versatile technology and equipment portfolio to design, develop, and optimize chemical processes and techni cal manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
According to Swiss GAAP FER 31 "Complementary Recommendation for Listed Public Companies", the reportable ope rating segments are determined using the segment reporting to the top management level for corporate management. DOTTIKON ES Group's top management level is the Board of Directors. In addition to its statutory tasks, the Board of Directors is responsible for the strategic focus and management of the Group. Strategic and important operational decisions of DOTTIKON ES Group are taken by the Board of Directors.
DOTTIKON ES Group builds on one single production site with the strategy of performance leadership as specialist for hazardous reactions. DOTTIKON ES Group mainly executes strongly heterogeneous projects with a focus on the exclusive synthesis of fine chemicals. Therefore, a differentiation in several operating segments is not informative.
The financial reporting to the Board of Directors is prepared in a single segment. DOTTIKON ES Group allocates resources and assesses their performance on entity level.
Therefore, the required information according to Swiss GAAP FER 31.8 "Segment Reporting" is shown in the Group Financial Statements.
2 PERSONNEL EXPENSES
CHF thousand/April-March
2018/19
2019/20
Wages and salaries
56'484
59'453
Employee benefits
4'366
4'540
Social security
4'671
4'904
Other personnel expenses
746
955
Personnel expenses
66'267
69'852
3 OTHER OPERATING EXPENSES
CHF thousand/April-March
2018/19
2019/20
Rent
198
324
Repair and maintenance
9'343
9'707
Insurance, duties, and fees
1'238
1'283
Administration and promotion
2'230
2'409
Loss on disposal of non-current assetsA
321
465
Supplies
4'630
5'025
Various other operating expensesB
1'699
2'025
Other operating expenses
19'659
21'238
Mainly includes replacement of plant and building components with carrying amounts
Mainly includes costs for waste disposal, selling, and food for staff restaurant
4 FINANCIAL RESULT
Financial income includes the following:
CHF thousand/April-March
2018/19
2019/20
Interest incomeA
35
1'564
Income from foreign currency valuation
765
365
Financial income
800
1'929
Reporting year 2019/20: thereof CHF 1'559 thousand due to changes in the value of the employer contribution reserve, mainly from interest bearing
Financial expenses include the following:
CHF thousand/April-March
2018/19
2019/20
Bank charges, interest expensesA
566
13
Expenses from foreign currency valuation
810
407
Financial expenses
1'376
420
Previous year: thereof CHF 551 thousand due to changes in the value of the employer contribution reserve, mainly from interest bearing
Foreign exchange gain recognized in the income statement amounts to CHF 94 thousand during the reporting year 2019/20 (previous year: foreign exchange gain of CHF 187 thousand) and is allocated to the following positions of the income statement ("+" foreign exchange gain; "-" foreign exchange loss)
Net sales CHF +39 thousand (previous year: CHF +78 thousand)
Material expenses CHF +97 thousand (previous year: CHF +154 thousand)
Financial income CHF +365 thousand (previous year: CHF +765 thousand)
The applicable tax rate corresponds to the tax rate at the headquarters of DOTTIKON EXCLUSIVE SYNTHESIS AG, which is domiciled in Switzerland and which most significantly affects the Group result in the long term
Reporting year 2019/20: effect of additional taxable deductions of research and development expenses 2019/20 due to changes in the tax law as of January 1, 2020, "tax proposal 17" (TP17)
Deviations mainly result from different allocation of the results of the Group companies
Reporting year 2019/20: higher income tax rate of DOTTIKON ES HOLDING AG at the domicile by abolishing the holding privilege due to changes in the tax law as of January 1, 2020, "tax proposal 17" (TP17)
CHF thousand/April-March
2018/19
2019/20
Attributable to the following positions:
Current income tax
3'883
5'117
Deferred income tax
-536
-280
Recognized income tax expenses
3'347
4'837
Deferred tax liabilities are attributable to the following positions:
CHF thousand/31.03.
2018/19
2019/20
Property, plant and equipment
14'503
13'107
Inventories
4'991
5'852
Non-current provisions
3'033
3'033
Assets from employer contribution reserve
7'865
8'155
Other balance sheet positions
729
658
Deferred tax liabilitiesA
31'121
30'805
Only includes deferred tax liabilities; there are no deferred tax assets
22 Notes DOTTIKON ES Group
6 TRADE RECEIVABLES
Trade receivables are value adjusted as follows:
CHF thousand/31.03.
2018/19
2019/20
Trade receivables, gross
41'245
35'179
Individual value adjustments
0
0
Overall value adjustments
-43
-35
Trade receivables, net
41'202
35'144
At the balance sheet date, as in the previous year, there were no bad debts to be written off. Receivables which are not due and not subject to individual value adjustments are mainly receivables arising from long-standing customer relationships. Based on past experience, DOTTIKON ES Group does not anticipate any significant defaults.
At the balance sheet date, the aging structure of trade receivables which are not subject to individual value adjustments was as follows:
CHF thousand/31.03.
2018/19
2019/20
Not yet due
36'537
32'313
1 to 30 days overdue
4'300
2'859
31 to 60 days overdue
44
7
61 to 90 days overdue
26
0
More than 90 days overdueA
338
0
Total
41'245
35'179
Previous year: receivables fully paid in April 2019
Condensed Annual Report 2019/20
7 INVENTORIES
CHF thousand/31.03.
2018/19
2019/20
Raw materials
12'985
14'606
SuppliesA
6'121
6'246
Trading goods
218
119
Semi-finished goods
22'046
26'329
Finished goods
25'718
31'356
Inventories
67'088
78'656
Mainly includes precious metals in the form of catalysts for production purposes
Value adjustments deducted from the above-mentioned inventory balances amount to CHF 3'954 thousand as of March 31, 2020 (previous year: CHF 4'149 thousand).
23 Notes DOTTIKON ES Group
Condensed Annual Report 2019/20
8 DEVELOPMENT OF PROPERTY,
Land A
Buildings
Technicalplant and machinery
property,Other plant and equipment
Plantsunder construction B
Total
PLANT AND EQUIPMENT
CHF thousand
Cost
Balance 01.04.2018
8'699
147'366
343'046
13'936
38'844
551'891
AdditionsC
0
2'710
10'159
1'064
38'400
52'333
DisposalsD
0
-1'005
-5'057
-495
-4'000
-10'557
Reclassifications
0
985
3'685
126
-4'818
-22
Balance 31.03.2019
8'699
150'056
351'833
14'631
68'426
593'645
Balance 01.04.2019
8'699
150'056
351'833
14'631
68'426
593'645
AdditionsC
0
4'672
8'786
1'166
24'292
38'916
Disposals
0
-478
-11'921
-265
0
-12'664
Reclassifications
0
28'851
12'849
6'904
-48'631
-27
Balance 31.03.2020
8'699
183'101
361'547
22'436
44'087
619'870
Depreciation, accumulated
Balance 01.04.2018
0
-83'122
-226'599
-10'694
0
-320'415
AdditionsD
0
-2'727
-12'024
-758
-4'000
-19'509
DisposalsD
0
936
4'811
495
4'000
10'242
Reclassifications
0
0
0
0
0
0
Balance 31.03.2019
0
-84'913
-233'812
-10'957
0
-329'682
Balance 01.04.2019
0
-84'913
-233'812
-10'957
0
-329'682
Additions
0
-3'569
-13'774
-1'365
0
-18'708
Disposals
0
397
11'537
265
0
12'199
Reclassifications
0
0
0
0
0
0
Balance 31.03.2020
0
-88'085
-236'049
-12'057
0
-336'191
Carrying amounts
01.04.2018
8'699
64'244
116'447
3'242
38'844
231'476
31.03.2019
8'699
65'143
118'021
3'674
68'426
263'963
31.03.2020
8'699
95'016
125'498
10'379
44'087
283'679
AShare of unbuilt land as of 31.03.2020: CHF 1'854 thousand (31.03.2019: CHF 1'854 thousand and 01.04.2018: CHF 1'854 thousand) as well as share of built land as of 31.03.2020: CHF 6'845 thousand (31.03.2019: CHF 6'845 thousand and 01.04.2018: CHF 6'845 thousand)
BThereof prepayments for plants under construction, 31.03.2020: CHF 0 thousand (31.03.2019: CHF 0 thousand and 01.04.2018: CHF 362 thousand) CCapital expenditure reflects cost of acquired property, plant and equipment (without consideration of cash outflow)
DPrevious year: within the scope of the planning of the basic design for a new multipurpose plant, the project had to be redimensioned due to challenging subsoil foundation properties. CHF 4'000 thousand of accumulated planning work within plants under construction were not able to be capitalized and have been depreciated as well as derecognized
The insurance value of property, plant and equipment amounts to CHF 643'393 thousand as of March 31, 2020 (previous year: CHF 617'954 thousand). Capital commitments for property, plant and equipment amount to CHF 14'275 thousand as of March 31, 2020 (previous year: CHF 17'117 thousand). There was no impairment on property, plant and equipment in the reporting year 2019/20 (previous year: as mentioned in footnote D, property, plant and equipment was impaired by CHF 4'000 thousand). No interests were capitalized in the reporting and the previous year.
24 Notes DOTTIKON ES Group
Condensed Annual Report 2019/20
9 DEVELOPMENT OF INTANGIBLE ASSETS
Software
Total
CHF thousand
Cost
Balance 01.04.2018
3'169
3'169
AdditionsA
398
398
Disposals
-18
-18
Reclassifications
22
22
Balance 31.03.2019
3'571
3'571
Balance 01.04.2019
3'571
3'571
AdditionsA
68
68
Disposals
-90
-90
Reclassifications
27
27
Balance 31.03.2020
3'576
3'576
Amortization, accumulated
Balance 01.04.2018
-2'657
-2'657
Additions
-197
-197
Disposals
12
12
Reclassifications
0
0
Balance 31.03.2019
-2'842
-2'842
Balance 01.04.2019
-2'842
-2'842
Additions
-232
-232
Disposals
90
90
Reclassifications
0
0
Balance 31.03.2020
-2'984
-2'984
Carrying amounts
01.04.2018
512
512
31.03.2019
729
729
31.03.2020
592
592
ACapital expenditure reflects cost of acquired intangible assets (without consideration of cash outflow)
No development costs were capitalized in the reporting year 2019/20 and the previous year since no capitalization criteria were met. Expenses for research and development of CHF 18'321 thousand (previous year: CHF 16'129 thousand) were charged to the income statement. Capital commitments for intangible assets amount to CHF 39 thousand as of March 31, 2020 (previous year: CHF 131 thousand). There was no impairment on intangible assets in the reporting year 2019/20 and the previous year. No interests were capitalized in the reporting and the previous year.
25 Notes DOTTIKON ES Group
Condensed Annual Report 2019/20
10 PROVISIONS
Environmental provisions for soil rehabilitation (former storage tanks) were recognized and have changed as follows:
CHF thousand
2018/19
2019/20
Balance 01.04.
5'485
5'470
Additional provisions charged to income
0
0
Consumption with neutral impact on income
-15
-2
Unused amounts reversed and released to income
0
0
Balance 31.03.
5'470
5'468
thereof current
50
48
thereof non-current
5'420
5'420
11 SIGNIFICANT EVENTS AFTER THE BALANCE SHEET DATE
The Group Financial Statements were approved for issue by the Board of Directors on May 14, 2020. They are subject to approval by the Annual General Meeting. No significant events have occurred between March 31, 2020, and May 14, 2020, that would require an adjustment of the Group's carrying amounts of assets and liabilities or that would need to be disclosed under this heading.
27 DOTTIKON ES GroupCondensed Annual Report 2019/20
Corporate Governance
28 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
Corporate Governance (condensed)
29 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
Board of Directors
CEO
Dr. Markus Blocher
CFO
Human Resources
Marlene Born
Karin Krause
Business
Processes &
Purchasing
Production
Quality Management
Development
Technologies
Dr. Thomas Rosatzin
Bruno Eugster
Dr. Knut Hildebrandt
Dr. Stephan Kirschbaum
Dr. Urs BrändliA
As of January 2020, until December 2019 Dr. Max Bachmann
GROUP STRUCTURE AND SHAREHOLDERS Group structure
DOTTIKON ES Group manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. DOTTIKON ES Group is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. DOTTIKON ES Group uses, maintains, and continuously expands its versatile technology and equipment portfolio to design, develop, and optimize chemical processes and techni cal manufacturing procedures for the rapid scale-up from kilograms to multi-tons in order to produce and deliver the respective market volumes.
The operating management structure of the Group is organized by functions according to the illustration on the left. DOTTIKON ES HOLDING AG, holding company of DOTTIKON ES Group, has its domicile in Dottikon and is listed on the SIX Swiss Exchange (DESN; security number 2073900; ISIN CH0020739006). The share capital amounts to CHF 127'264.40 as of March 31, 2020 (previous year: CHF 127'264.40). The market capitalization as of March 31, 2020, is CHF 819'582'736 (previous year: CHF 566'326'580). As in the previous year, there are no further listed companies in the Group.
DOTTIKON ES HOLDING AG has investments in the following companies
DOTTIKON EXCLUSIVE SYNTHESIS AG Domicile in Dottikon/share capital CHF 102'000 Investment share of 100 percent/fully consolidated Branch/purpose: chemicals/process development, manufacturing, and sale of chemical intermediates and active pharmaceutical ingredients
DOTTIKON ES MANAGEMENT AG
Domicile in Dottikon/share capital CHF 100'000 Investment share of 100 percent/fully consolidated Branch/purpose: chemicals/management of investment companies, as well as review and assessment to evaluate their strategies
DOTTIKON ES AMERICA, Inc.
Domicile in Delaware, USA/share capital CHF 0 Investment share of 100 percent/fully consolidated Branch/purpose: chemicals/business development, marketing, and consulting services for investment companies
SYSTAG, System Technik AG
Domicile in Rüschlikon/share capital CHF 410'000 Investment share of 49.7 percent (previous year: 47.1 percent)A/equity method
Branch/purpose: automated process technology/ development and manufacturing of integrated solutions for automated chemical process development as well as software and engineering services
In the reporting year 2019/20, SYSTAG, System Technik AG acquired and
recognized own shares in the balance sheet. As a result, as of March 31, 2020, DOTTIKON ES HOLDING AG has a participation of 49.7 percent in SYSTAG,
System Technik AG
30 Corporate Governance DOTTIKON ES Group
Significant shareholders
The following shareholders hold more than 3 percent of the registered share capital:
In % of total share capital of
DOTTIKON ES HOLDING AG
31.03.2019
31.03.2020
Markus Blocher, WollerauA
71.7
71.8
Peter Grogg, Hergiswil NWB
7.0
7.0
Miriam Baumann, Rheinfelden
5.1
5.1
UBS Fund Management (Switzerland) AG, Basel
4.5
4.6
Condensed Annual Report 2019/20
Participations of the members
Number of
Number of
of the Board of Directors, Advisory
registered shares
registered shares
Board, and Senior Management
31.03.2019
31.03.2020
Markus BlocherA
Chairman of the Board of Directors
CEO/Managing Director
912'973
914'212
Thomas Früh
Deputy Chairman of the Board of Directors
non-executive
50
50
Alfred Scheidegger
31 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
BOARD OF DIRECTORS
MEMBERS OF THE BOARD OF DIRECTORS OF DOTTIKON ES HOLDING AG
As of March 31, 2020
Name
Nationality
Born
Position
Title
Term of office
Markus Blocher
Swiss
1971
Chairman, executiveA
Dipl. Chem. ETH, Dr. sc. nat. ETH
2010-2020
Thomas Früh
Swiss
1957
Deputy Chairman, non-executive
Dipl. Chem. ETH, Dr. sc. nat. ETH
2012-2020
Alfred Scheidegger
Swiss
1957
Member, non-executive
Dr. phil. II
2011-2020
CEO/Managing Director
Holds 59.4% as of 31.03.2020 (31.03.2019: 54.4%) through EVOLMA Holding AG, Wollerau
Through Ingro Finanz AG, Bubendorf
Participations of members of the Board of Directors, Advisory Board, Senior Management, and persons related to them
Members of the Board of Directors, Advisory Board, Senior Management as well as their related parties hold the following registered shares of DOTTIKON ES HOLDING AG as of March 31, 2020 (previous year: March 31, 2019):
Member of the Board of Directors
non-executive
5
5
Bernhard UrwylerB
Advisory counselor
non-executive
-
0
Marlene Born
CFO
598
699
Karin Krause
Head of Human Resources
66
122
Stephan Kirschbaum
Head of Business Development
1'211
1'312
Max BachmannC
Head of Processes & Technologies
535
-
Urs BrändliD
Head of Processes & Technologies
-
302
Thomas Rosatzin
Head of Purchasing
187
246
Bruno Eugster
Head of Production
434
527
Knut Hildebrandt
Head of Quality Management
315
301
Total members of the Board of Directors,
Advisory Board, and Senior Management
916'374
917'776
Holds 756'424 registered shares as of 31.03.2020 (31.03.2019: 691'733 registered shares) through EVOLMA Holding AG, Wollerau
As of March 2020; there were no participation positions to be disclosed as of March 31, 2019
Until December 2019; there are no participation positions to be disclosed as of March 31, 2020
As of January 2020; there were no participation positions to be disclosed as of March 31, 2019
Markus Blocher
Professional background/career
Chairman of the Board of Directors of
Since 2012
DOTTIKON ES HOLDING AG
Member of the Board of Directors of
2010-2012
DOTTIKON ES HOLDING AG
Since 2003
CEO of today's DOTTIKON ES GroupA
Responsible for special projects
2002-2003
in the EMS Group
2000-2002
Consultant, McKinsey & Company, Zurich
See Notes "Senior Management"
Other activities and binding interests
Chairman of the Board of Directors of EVOLMA Holding AG
Chairman of the Board of Directors of SYSTAG, System Technik AG
President of the Foundation Board of the pension plan of DOTTIKON ES Group and of the social welfare foundation of DOTTIKON EXCLUSIVE SYNTHESIS AG
Chairman of the Board of Directors of frugan Holding AG as well as of its subsidiary Evide AG (formerly agrofrucht-Inn AG)
Chairman of the Board of Directors of agrocult AG (until May 2019) and cultivport AG (until June 2019)
Thomas Früh
Professional background/career
Deputy Chairman of the Board of Directors of
Since 2012
DOTTIKON ES HOLDING AG
CEO of Bachem Group and
2012-2019A
Bachem Holding AG
2001-2012
COO of Bachem AG, Switzerland
COO of Bachem Bioscience, Inc.,
1998-2000
King of Prussia, Pennsylvania USA
Head of Production Department,
1997-1998
Bachem AG, Switzerland
Department Head Crop Protection
1994-1997
Research, Ciba, Basel
1990-1994
Project Leader Pharma Research Ciba, Japan
Until December 2019
Other activities and binding interests
Member of the Board of Directors of Bachem Holding AG (as of April 2020)
Chairman of the Board of Directors of MFC Beteiligungs AG (as of April 2020)
President of the Foundation Board of the foundation SimplyScience
Vice president of the business association scienceindustries
Board member of Handelskammer beider Basel (HKBB)
Until December 2019 Chairman of the Board of Directors of Bachem AG (Switzerland), Bachem Americas, Inc. (USA), Bachem (UK) Ltd., and of Bachem Japan K.K. (Japan)
Until December 2019 Director of Bachem Distribution Services GmbH (Germany)
32 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
33 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
Alfred Scheidegger
Professional background/career
Member of the Senior Management of
Since 2017
Nextech Invest AG
Member of the Board of Directors of
Since 2011
DOTTIKON ES HOLDING AG
1998-2017
Founder and CEO of Nextech Invest AG
Administrative Director and member of
1995-1998
the Board of ETH Zurich
CEO Swiss Scientific Computing Center
1992-1995
(CSCS), Manno
1987-1991
Project Leader Ciba-Geigy in Basel and Japan
Other activities and binding interests
The 2 members of the Board of Directors, Thomas Früh and Alfred Scheidegger, did not have any executive function within the DOTTIKON ES Group in the past 3 years before the reporting year 2019/20. Neither of them nor any related party had significant business relations with DOTTIKON ES Group in the past years since being elected to the Board of Directors of DOTTIKON ES HOLDING AG.
In the reporting year 2014/15, DOTTIKON EXCLUSIVE SYNTHESIS AG and Bachem AG signed a cooperation agreement for the development, manufacturing, and distribution of amino acids and their derivatives. Despite personnel relations with DOTTIKON EXCLUSIVE SYNTHESIS AG, Bachem AG is not qualified as a related party. To provide higher transparency,
SENIOR MANAGEMENT
MEMBERS OF THE SENIOR MANAGEMENT OF DOTTIKON ES GROUP
As of March 31, 2020
Name
Nationality
Born
Function
Title
Member since
Markus Blocher
Swiss
1971
CEO/Managing Director
Dipl. Chem. ETH, Dr. sc. nat. ETH
2003
Marlene Born
Swiss
1975
CFO
Eidg. dipl. Expertin in Rechnungslegung/Controlling 2006
Karin Krause
Swiss
1968
Head of Human Resources
MAS Human Resource Management FH
2017
Stephan Kirschbaum
German
1967
Head of Business Development
Dipl. Chem., Dr. rer. nat.
2010
Urs BrändliA
Swiss
1960
Head of Processes & TechnologiesB
Dipl. Chem. ETH, Dr. sc. nat. ETH
2020
Thomas Rosatzin
Swiss
1962
Head of Purchasing
Dipl. mikrobiol., Dr. sc. nat. ETH, MBA
2014
Bruno EugsterC
Swiss
1955
Head of Production
Chemiker HTL
1997
Knut Hildebrandt
German
1958
Head of Quality Management
Dipl. Chem., Dr. rer. nat.
1999
As of January 2020
Until December 2019 Max Bachmann
Until May 2020
Chairman of the Board of Directors of Nextech Holding AG and Nextech Invest AG
Member of the Board of Directors of Nextech III GP AG
Director of Nextech Venture (Principals) Limited, Jersey
Representative of the partner with unlimited liability of Nextech III Oncology Kommanditgesellschaft für kollektive Kapitalanlagen
Member of the Board of Directors of Cleave Biosciences, Burlingame, CA, USA (until May 2019)
Member of the Foundation Board of Rising Tide Foundation
the existence of a cooperation agreement is disclosed under this heading.
The composition of the Board of Directors of DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG is the same as the composition of DOTTIKON ES HOLDING AG.
Advisory counselor
As of March 1, 2020, DOTTIKON ES Group appointed Dr. Bernhard Urwyler as advisory counselor. Bernhard Urwyler holds a doctoral degree in chemistry and looks back on more than 30 years of experience in chemical development and production. He leads the chemical production unit of Syngenta CP Produktion Monthey SA, VS.
Markus Blocher
Professional background/career
Since 2003
CEO of today's DOTTIKON ES Group
Responsible for special projects
2002-2003
in the EMS Group
2000-2002
Consultant, McKinsey & Company, Zurich
1997-2000
Scientist and doctorate at ETH Zurich
Other activities and binding interests
Chairman of the Board of Directors of DOTTIKON ES HOLDING AG (see Notes "Board of Directors")
CEO of DOTTIKON EXCLUSIVE SYNTHESIS AG, DOTTIKON ES HOLDING AG, and DOTTIKON ES MANAGEMENT AG
Chairman of the Board of Directors of EVOLMA Holding AG
Chairman of the Board of Directors of SYSTAG, System Technik AG
President of the Foundation Board of the pension plan of DOTTIKON ES Group and of the social welfare foundation of DOTTIKON EXCLUSIVE SYNTHESIS AG
Chairman of the Board of Directors of frugan Holding AG as well as of its subsidiary Evide AG (formerly agrofrucht-Inn AG)
Chairman of the Board of Directors of agrocult AG (until May 2019) and cultivport AG (until June 2019)
34 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
35 Corporate Governance DOTTIKON ES Group
Condensed Annual Report 2019/20
Marlene Born
Professional background/career
Since 2006
CFO of DOTTIKON ES Group
2005-2006
Controller at DOTTIKON ES Group
Head of Accounting, Migros
2000-2005
Verteilzentrum Suhr AG, Suhr
2000
Controller, ABB Normelec, Zurich
Accountant, Treuhandbüro
1995-2000
Deragisch, Baden
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG, DOTTIKON ES HOLDING AG, and DOTTIKON ES MANAGEMENT AG
Member of the Foundation Board of the pension plan of DOTTIKON ES Group
Vice president of the social welfare foundation of
DOTTIKON EXCLUSIVE SYNTHESIS AG
Karin Krause
Professional background/career
Head of Human Resources of
Since 2015
DOTTIKON ES Group
Head of Human Resources,
2011-2015
Senn AG, Oftringen
Head of Financial Accounting and Human
2005-2011
Resources, Deputy CFO, Senn AG, Oftringen
Head of Financial Accounting and Human
2003-2005
Resources, Wematech AG, Wangenried
Accountant clerk,
1999-2003
Amcor Rentsch AG, Rickenbach
Human Resource clerk,
1995-1999
Amcor Rentsch AG, Rickenbach
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG
Stephan Kirschbaum
Professional background/career
Head of Business Development of
Since 2009
DOTTIKON ES Group
Head of Strategic Projects and Head of
Management Support HR&E in Wealth
2005-2009
Management & Swiss Bank, UBS AG, Zurich
Consultant and Engagement Manager,
1999-2005
McKinsey & Company, Munich DE
Research Scientist at University of
1997-1999
California, Santa Barbara USA
1994-1997
Doctorate at University of Karlsruhe DE
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG
Chairman of the Board of Directors and CEO of DOTTIKON ES AMERICA, Inc.
Urs Brändli
Professional background/career
Head of Processes & Technologies of
Since 2020A
DOTTIKON ES Group
Head of Research & Development of today's
2003-2019
DOTTIKON ES Group
Project Manager in Research & Development
1995-2003
at today's DOTTIKON ES Group
Head of Laboratory in Research & Develop-
1990-1995
ment at today's DOTTIKON ES Group
As of January 2020
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG and DOTTIKON ES MANAGEMENT AG (as of January 2020)
Thomas Rosatzin
Professional background/career
Since 2014
Head of Purchasing of DOTTIKON ES Group
2007-2013
CEO of RohnerChem (Rohner AG), Pratteln
2005-2007
COO of Induchem AG, Volketswil
Head Product Line Management,
2001-2005
Unaxis/ESEC, Steinhausen
Business Unit Manager Paper Processing
1995-2001
Chemicals, Dr. W. Kolb AG, Hedingen
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG
Member of the welfare application decision panel of Aeugst a. A.
Bruno Eugster
Professional background/career
Head of Production of today's
Since 1999A
DOTTIKON ES Group
Head of Technical Services of today's
1997-1999
DOTTIKON ES Group
Several leading positions at today's
DOTTIKON ES Group, lastly
1979-1997
Head of Production Facilities
Until May 2020
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG (until May 2020)
Member of the Board of the Chamber of Aargauische Industrie- und Handelskammer (AIHK), therein president of the section Freiamt (until December 2019)
Expert judge, labor court, canton Aargau (through December 2020)
Knut Hildebrandt
Professional background/career
Head of Quality Management of today's
Since 1999
DOTTIKON ES Group
Several leading positions at today's
DOTTIKON ES Group, lastly
1989-1999
Project Manager Production
Other activities and binding interests
Member of the Senior Management of DOTTIKON EXCLUSIVE SYNTHESIS AG
Changes in Senior Management in the reporting year 2019/20
On December 31, 2019, Max Bachmann handed over the Senior Management position of Head of Processes & Technologies to Urs Brändli upon reaching the official retirement age. Urs Brändli was appointed as member of the Senior Management and Head of Processes & Technologies on Jan- uary 1, 2020. Max Bachmann will continue to actively support DOTTIKON ES Group in the current phase of growth and capacity expansion and will be responsible for Debottlenecking and New Production Facilities Projects.
Information regarding the person of Max Bachmann can be found in the Condensed Annual Report 2018/19 on pages 37 and 38, available under the following internet link https:// dottikon.com/upload/PDF/Investors/Financial_Reports/EN/ annual_report_2018_19.pdf.
37 DOTTIKON ESCondensed Annual Report 2019/20
Investor Relations
Annual General Meeting for the Business Year 2019/20
July 3, 2020
Issue Half-Year Report 2020/21
November 27, 2020
Issue Annual Report 2020/21
May 28, 2021
Annual General Meeting for the Business Year 2020/21
July 2, 2021
DOTTIKON ES HOLDING AG is listed on the SIX Swiss Exchange.
Symbol: DESN
Security number: 2073900
ISIN: CH0020739006
Dottikon ES Holding AG
P.O. Box
5605 Dottikon
Switzerland
Tel +41 56 616 82 01
Fax +41 56 616 89 45
www.dottikon.com
Contact
Marlene Born, CFO investor-relations@dottikon.com
39 DOTTIKON ES
Condensed Annual Report 2019/20
DOTTIKON ES manufactures high-quality performance chemicals, intermediates, and exclusive active pharmaceutical ingredients (APIs) for the world's leading chemical and pharmaceutical industry. The company with its production site in Dottikon (Aargau, Switzerland) is specialized in hazardous reactions and positions itself as strategic development and manufacturing partner and performance leader. Its safety culture created over the past 105 years guides the innova tive use of hazardous reactions, low-temperature and high-pressure chemistry, as well as continuous processing in order to challenge, tighten, or shorten conventional chemical synthesis routes, improve selectivities, yields, and purities, and reduce waste. The versatile technology and equipment portfolio is used, maintained, and continuously expanded to design, develop, and optimize chemical processes and technical manufacturing procedures for the rapid scale- up from kilograms to multi-tons in order to produce and deliver the respective market volumes. DOTTIKON ES' one-site strategy allows reduced decision and communication pathways. This ensures rapid and efficient project development as well as clear and transparent data and process documentation and customer communication.
DISCLAIMER
IMPRINT
Statements on future events or developments, particularly on the estimation of future
Photography
business, reflect the view of the management of DOTTIKON ES HOLDING AG in the
Anja Wille-Schori, Zurich
moment of composition. Since these naturally contain uncertainties and risks, they are
www.anjawille.com
given without guarantee and any liability is denied. DOTTIKON ES HOLDING AG refus
es to actualize any forward-looking statements. The Internet version of these financial
Art Direction, Graphics & Typesetting
statements is exposed to fraudulent manipulation possibilities that are within such a
Raffinerie, Zurich
medium, and is therefore without guarantee. The comprehensive Annual Report is
www.raffinerie.com
available in German. Only the comprehensive German version submitted to the SIX
Dottikon ES Holding AG published this content on 29 May 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 May 2020 05:20:07 UTC
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
